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In the Community internal market, cosmetic products must be able to circulate freely and 
meet high quality and safety standards. 
The  new  provisions  of Council  Directive  93/35/EEC  amending  for  the  sixth  time 
Directive 76/768/EEC on the approximation of the laws of the Member States relating to 
cosmetic products are a consistent package designed to: 
provide  consumers,  the  supervisory  authorities  in  the  Member  States  and  the 
Commission with better information, notably through compiling an inventory of 
ingredients used in  cosmetic products, through mandatory  information labelling 
and  through  provision  by  the  national  supervisory  authorities  of a  dossier 
containing  information  on  the  product's  formula,  its  physico-chemical  and 
microbiological specifications, the method of manufacture, assessment of safety 
for human health, undesirable effects and proof of the claimed effect. 
assure a better level of quality and safety of products and their ingredients and 
hence a better level of consumer health protection. 
However, in  assessing safety for human health, the suffering and death of animals must 
be avoided wherever possible. 
Hence, Article 2 of Directive 76/768/EEC laid down the very clear principle of "safety 
of cosmetic  products for human  health".  This  requirement is  specified  in  Article 2 as 
amended by  Directive 93/35/EEC. 
·~ cosmetic product put on the marlcet within the Community lllll.ft not c1111.1e damage to 
Jumuua  health when applied under normal or reasonably foreseeable  conditions of use, 
taking account,  in particular, of the product's presentation, its labelling,  any instructions 
for its use and disposal as  well as  any  other indication or information provided by the 
manufacturer or his authorised agent or by any other person responsible for placing the 
product on the  Community marlcet." 
Article 4,  as  amended by  Directive  93/35/EEC,  concerns  respect for the  protection of 
animal life. 
"Without pre}ud,ice  to  their general obligations deriving from Article 2,  Member States 
shall prohibit the marlceting of cosmetic products containing: 
i)  ingredients or combinations ofiJJgredients tested on animals qfter 1 January  1988 
in order to meet the requirements of  this Directive." 
However,  Directive  93/35/EEC  stresses  the  need  to  offer the  consumer  a  degree  of 
protection  equivalent  to  that  obtained  by  animal  experiments.  It  also  lays  down 
obligations for the Commission, which must present draft measures aimed at putting back 
the  deadline for  prohibiting animal .experiments  if alternative  methods  have not been 
2 validated and legally accepted, and to present an annual report to the European Parliament 
and Council on trends in  this domain. 
"If there  has  been  insufficient progress  in  developing  satisfactory  methods to  replace 
animal testing,  and in  particular in  those  cases  where  alternative  methods of testing, 
despite all reasonable  endeavours,  have not been  scient~fically validated as  offering an 
equivalent level of  protection for the  consumer,  taking into account OECD toxicity test 
guidelines, the Commission shall,  by 1 January  1997,  submit drcift measures to postpone 
the date of  implementation of this provision, for a sufficient period,  and in any case for 
no less than two years,  in accordance with the procedure laid down in A rtic/e 10.  Before 
submitting such  measures,  the  Commission  will consult  the  Scientific  Committee  on 
Cosmetology." 
'The Commission shall present an  tliUUIIll  repolt to the Europeon  Parliament  on the 
Council on progress in the developllt8tlt,  validation and legal acceptance of  altemlllive 
methods to those involving experiments on anilllllb.  Tluit report slaall contain precise data 
on the number IIIUI  type of experiments relllling to cosmetic prodllcts Clln'ied  out on 
aniiiUIIs.  The  Member States  shall be  obliged to  collect the  infonnation in  addition  to 
collecting statistics as laid down by Directive 86/609/EEC on the protection of  animals 
used for experimental and other scientific purposes.  The Commission shall in particular 
ensure the development,  validation and legal acceptance of  experimental methods which 
do  not use live animals. " 
This report will examine in tum: 
the objectives and individual stages involved 
the  safety  of cosmetic  ingredients,  the  concept of risk  and  scientific  methods 
available for assessing safety 
the actors 
the initiatives 
the state of play 
statistical collection of experiments on  animals 
progress achieved as of October 1994 
conclusions. 
B.  OBJECfiVES AND STAGES 
The Commission is in the unenviable position of having to reconcile provisions relating 
to  better protection of human health  with  animal  welfare, the  main objective being to 
encourage  the  development,  scientific  validation  and  legal  acceptance  of altemative 
meehodoloaies  which  will  offer consumen  a  level  of protection  equivalent  to  Chat 
obtained Chroup eiperiments on animal models. 
3 Alternative methods (AM) are defined" as all modifications to existing internationally and 
scientifically approved tests with a view to: 
( 1)  reducing the number of animals used 
(2)  refining existing protocols, so as to  reduce animal suffering 
(3)  replacing tests on animals 
in the performance of toxicological tests necessary for evaluating the safety of  substances 
and/or combinations of substances liable to  imperil human health. 
This concept indicates that the  development of alternative methods is not confined to 
replacing live animals, although this is the objective of the work done in implementing 
Directive 93/95. 
Methods whic:h do not use live animals (c:ase 3) inc:lude ''in vitro" methods and computer 
simulations (mathematical models). 
"In vitro" methods include simple biological systems in the form of bacteria, cultures of 
cells or animal or human tissues, organotypical cultures, or systems using artifical media 
(reconstituted skin); these methods may also be physical and chemical tests (alkaline-acid 
reserve, etc.). 
The most widely used tissues and organs are: 
•  skin cultures (mouse, rabbit, man, rat, pig, chicken, etc.) 
•  cell cultures from bone marrow, lungs, liver, skin (keratinocytes); they may be cell 
lines or primary cells (rat, mouse, hamster, etc.). 
•  embryos (chicken, fish, frog, rat, etc.) 
•  eyes (cow, rabbit, mouse, etc.) 
One big advantage of  computer analysis programmes is the ability to manipulate the large 
number of variables in various experiments and to develop QSAR•• studies to predict in 
vitro and/or in  vivo toxic potential of untested substances, etc. 
The  replacement  of toxicity  tests  on  animal  models  by  in  vitro  tests  involves  the 
following stages: 
l  DEVEWPMENT OF IN  VITRO TESTS 
Toxic effects observed in vivo are complex and involve several mechanisms at cell level. 
In the case of in vitro tests, the test system is isolated from the animal and action at cell 
level  is  simplified and  more specific,  but incomplete  by  comparison  with the effects 
observed in vivo. 
Russell and Burch 1959 . 
••  Quantitative Structure Activity Relation 
4 In  vitro studies are  said to  constitute a "mechanistic"  approach,  i.e.  they  are based on 
biomechanical  mechanisms at cell  level  with  biological  consequences corresponding to 
an  in  vivo  toxic  effect.  However,  certain  in  vitro  tests  are  based  on  an  observed 
phenomenon approach rather than on  mechanisms which are not always known. 
Given this mechanistic approach, the test (or battery of complementary tests) developed 
must cast light on the fundamental biological consequences of to a given toxic effect and 
it  must  be  possible to  correlate the  results  with  toxicity  data on  animals  in  vivo  and 
interpret them in terms of toxicity for  man. 
2  VALIDA110N 
No  matter  what  agency  is  responsible  for  coordinating  the  validation  of alternative 
methods,  validation is  the  complex  process  via which  the  ~levance, ~liability  and 
reproducibility  of a  test developed  for roldine  application  and  lqal acceptance  are 
assessed and monito~d. 
In  1990 the OECD published a general  report on the scientific criteria for validating in 
vitro toxicity tests designed to contribute to the discussions· on the validation process: 
The major stages of validation are: 
an intra-labomtory evaluation designed to standardise the test protocol, to establish 
feasibility in regard to the objective in mind and the reproducibility of the results 
for a given substances within a given laboratory 
an  inter-lahomtory  evaluation  designed  to  verify  reproducibility  m  several 
laboratories 
development  of test  databases,  which  are  a  scientific  tool  for  analysing  and 
categorising the findings and which are mainly used to compare data derived from 
various studies of cell toxicity, to establish in vitro/in vivo correlations, to study 
the  applicability  of the  method  to  substances  belonging  to  different chemical 
classes,  to  determine  sensitivity  and  predictability  in  regard  to  an  in  vivo 
biological consequence. 
evaluation of  the results. 
The  agencies  responsible  for  validation  work  observe the principles  developed  in  the 
Am den workshop report reproduced in  Annex  1. • A second workshop has been held at 
Amden under the auspices of the ECV AM.  The report on the second workshop will  be 
published in  A  TLA in January  1995. 
Ilalls M., Blaauber B.,  Frazier J., Lamb D., Reinhardt C., Roberfroid M.,  Schmid B., Spielmann H., 
Stammati A.L.  and Walum E.  (1990). 
Amden Report.: Report and recommendations of the CAATIERGATI workshop on the validation of 
toxicity test procedures. ATLA  18, p.  313-337. 
5 A validation exercise is considered complete when these stages have been successfully 
terminated and  when  the  results  correspond exactly  to  the objectives laid down at the 
beginning of the exercise. 
3  LEGAL ACCEYI'ANCE 
A proposal  for  a new guideline or for  revising  an  existing guideline from the OECD, 
must  undergo  a  critical  evaluation of its  scientific justification,  its sensitivity  and  its 
reproducibility. 
The OECD procedure for  adopting alternative methods is subject to the same criteria. 
This is a multi-stage procedure which  generally takes between one and three years.  It 
requires  a  consensus  within  the  scientific  community  of the  25  Member  States,  and 
acceptance,  by  the  regulatory  agencies  in  Northern  America,  Europe  and  Japan,  of 
alternative  methods  as  substitutes  to  animal  experiments  in  evaluating  the  safety  of 
substances belonging to different classes. 
For example, the OECD secretariat began revising the genetic toxicology methods at the 
request of the European Commission in  1991. Three meetings have been held (London, 
30 November - 2 December 1992, Ottowa, 31  January - 2 February 1994 and Rome 19 -
23  September 1994) with a view to completing the review, which should be finalised in 
1995. 
C.  SAFElY OF COSMETIC INGREDIENTS AND mE CONCEYI' OF RISK 
To get a better picture of the state of play, it is useful to recall the legal backdrop to the 
assessment of the safety of ingredients used in  cosmetic products, the different aspects 
of toxicity  to  be examined,  the scientific  methods available for  evaluating safety, the 
definition  of cosmetic  product  within  the  meaning  of Directive  76/768/EEC  and the 
concept of risk. 
1  EVALUATION OF COSMETIC INGREDIENTS 
1.1  Cosmetic ingredients in annexes to Directive 76/768/EEC 
The Cosmetic Products Directive includes annexes with a list of  prohibited substances and 
a list of substances that are authorised under certain conditions. 
Substances which are not included on these lists are authorised a priori with the exception 
of three classes of substances to which the human skin is considered to be particularly 
sensitive, and for which positive lists exist: colouring agents, preservatives and UV filters. 
Before being entered in one of these annexes, which are regularly updated in a procedure 
involving a Committee on Adaptation to Technical Progress, the Scientific Committee on 
Cosmetology (SCC), created by  Commission Decision of 19 December 1977, must be 
consulted and deliver an opinion on the assessment of safety for human health of these 
substances. The SCC's evaluation takes into accomtt experimental toxicity data, the type 
and level of exposure in  cosmetic usage, applying its own guidelines. 
6 Council Directive 93/35/EEC amending for the sixth time Directive 761768/EEC contains 
a supplementary instrument designed to make the finished product better and safer in the 
form of provisions mandating the national supervisory authorities to make available an 
information  dossier,  which  must  inter alia contain  a safety  evaluation of the finished 
product. However this is largely based on evaluation of toxicity and safety data relating 
to the ingredients. The information dossier.will be essential after 1 January 1997, the date 
on  which  cosmetic  products  which  do  not  conform  to  the  provisions  of 
Directive 93/35/EEC will no longer be allowed to be marketed. 
Tbe -ic  toxicity ...  piVvided roria  Cbe pideliaes rorev  ........  Cbe nt'ety or  cosmetic 
produca me described below: 
The test procedures are described in OECD monographs and in Directives  87/302/EEC 
and  92/69/EEC,  except  for  the  photomutagenicity  tests,  photoirritation  tests, 
photosensitisation tests and percutaneous absorption tests. 
1. 
2. 
Acute toxicity, oral route [or inhalation]  - OECD 401-
All adverse effects produced by oral administration (or via inhalation) of a single 
dose or multiple doses of substances, administered within 24 hours. 
Selected species: rat 
LD50  is the dose of the substance administered by oral route (LC50  by inhalation) 
which causes the death of 500/o of the animals. 
Fixed dose method - OECD 410 
The in vivo fixed dose method was accepted by the OECD.  It  has been approved 
with the preliminary screening test which provides information on the dose to be 
applied in the main study. 
Percutaneous absorption  - Draft -
Percutaneous absorption is the process by  which a substance applied to the skin 
penetrates through the stratum corneum and enters the bloodstream. 
Selected species:  rat 
A  substance's  percutaneous  absorption  factor  is  the  quantity  of the  substance 
which is biologically available at systemic level after epicutaneous application. 
Because of the  decisive role of data on percutaneous absorption, the  SCC has 
prepared a document that critically analyses existing test methods. 
3.  Skin irritation  - OECD 404 -
Reversible inflammatory changes to the skin following epicutaneous application 
of the substance to be tested. 
Selected species: albino rabbit 
7 4.  Eye irritation  - OECD 405  -
Reversible changes to the eye following application of a substance to be tested to 
the anterior surface of the latter. 
Selected species:  albino rabbit 
5.  Skin sensitisation  - OECD 406 -
6. 
Secondary  immunological  cutaneous  reaction  on  contact  with  the  substance 
(allergic contact eczema) 
Selected species:  guinea-pig 
Sub-chronic toxicity, oral route (or inhalation)  - OECD 408 - (413) 
Complex of adverse effects resulting from repeated and daily administration of a 
substance by  oral route (or by  inhalation) during part of the lifetime of the test 
animals (not exceeding  10%). 
Selected species:  rodents, in particular the rat 
The 90-day sub-chronic toxicity tests provide information on the likely effects of 
repeated exposure over a limited period of time, the target organs, the possibility 
of cumulative effects and the no  toxic effect level. 
No observed adverse effect level (NOAEL) is the maximum dose of  the substance 
which can be used in a test without producing harmful effects. 
7.  Mutagenicity (photomutagenicity of UV filters)  -OECD 471 -472- 473- 476 
Modifications  of the  information  content  of the  genetic  material  (DNA,  i.e. 
desoxyribonucleic  acid)  transmitted  to  following  generations  of  cells  or 
individuals. 
Photomutagenicity  refers  to  all  modifications to  the information content of the 
genetic material in the presence of UV radiation. 
In-vitro test systems: 
gene mutations: 
chromosome aberrations: 
bacteria 
mammal cells 
mammal cells· 
8.  Cutaneous photosensitivity (for UV filters) 
Photoirritation  or phototoxicity  is  the  reaction  of the  skin  after  epicutaneous 
application of a chemical substance and exposure to light. 
Cutaneous photoallergy or photosensitisation is a skin reaction after percutaneous 
application of a chemical substance and exposure to light, involving the immune 
system. 
Selected species:  guinea-pig, rabbit, mouse. 
8 9.  Clinical data 
Data on  man  when available, for example data on allergic sensitivity. 
In the cae of potenti.a onll absorption or  sianificant cutaneous absorption, and dependina 
on die ~sulCI of  in-vitro mqenicity 1ests, supplementaly information may be necessary. 
10.  Toxicokinetics  - OECD 417-
Study of the absorption, distribution, excretion and metabolism of a substance. 
Selected species: rodents, in particular the rat. 
11.  Teratogenesis, reproduction, carcinogenesis and additional genetic toxicity 
Teratogenesis  - OECD 414 
Permanent  functional  or  structural  anomalies  caused  by  administration  of a 
substance during gestation. 
Selected species:  rat, mouse, hamster, rabbit 
Reproduction over one generation (OECD 415) and over two generations (OECD 
416) 
Effects of the test substance on  reproductive functioning· in  males and females 
Reproduction tests provide preliminary information on the toxic effects of the test 
substance,  on  development,  neonatal  morbidity,  mortality,  behaviour  and 
teratogenesis. 
Selected species:  rat, mouse 
Carcinogenesis  - OECD 451-
Observation of test animals  during  most of their lives  to  monitor the  possible 
development of neoplastic lesions after or during exposure to different doses of 
a test substance to be administered via the appropriate route. 
Selected species:  at least two species, rat and mouse. 
Additional in vivo genetic toxicity  - OECD 474-475-478-483-484-485-
Harmful (direct and indirect) effects on genetic material which are not necessarily 
associated with mutagenicity. 
Selected species:  hamster, mouse, guinea-pig 
Most chemical carcinogens cause DNA lesions as well as gene and chromosome 
mutations. 
The transformation of mutated cells into a cancerous state depends on other stages 
(promotion, progression) whose mechanisms are less well-known. 
9 A  safety  ~ia  is  calculated for  hair  dyes,  preservatives and  sun  filters,  taking  into 
account  the  no  adverse  effect  level  dose  obtained on  the  basis of toxicity  studies  at 
appropriate repeated doses, percutaneous absorption data and exposure data resulting from 
normal and intensive use communicated by  COLIPA. 
1.2  Cosmetic ingredients subject to notification in accordance with the 7th amendment 
to Dangerous Substances Directive 92/32/EEC 
Although the Dangerous Substances Directive does not apply to cosmetic products in their 
finished state, any "substance"  placed on the market after 18.9.1981  intended (notably) 
to be included in a cosmetic product, must be notified to the competent national authority 
of the Member State in which it is produced or imported into the EEC, in line with the 
provisions of Directive 92/32/EEC. 
The toxicity data required for notification depend on annual tonnage in the EC. 
The test procedures are described in Directives 87/302/EEC and 92/69/EEC and in the 
OECD monographs. 
2  EUROPEAN DEFINmON OF COSME'TIC PRODUCTS AND CONCEPI' OF 
"IUSK" 
It is useful to remember why cosmetic products which seem harmless may imperil human 
health. 
Cosmetic products are defined in  Article 1 of Directive 93/35/EEC: 
'~ "cosmetic product" shall mean any substance or prepatrllion intended to be placed in 
contact with the various extemaJ parts of  the human body  (epident~is, hair system, nails, 
lips and extemal genital organs)  or with the  teeth and mucous membmnes of the om/ 
cavity with a view  exclusively or mainly to  cleaning them,  peifuming them,  changing 
their appeamnce and/or correcting body odours and/or protecting them  or keeping them 
in good condition. " 
1bis definition of cosmetic pnHiucts coven a veey wide raae of produds, iadudiaa: 
classical make-up products 
perfumes 
products for use on the hair 
hygiene and toilet products (including soap, toothpaste, pre-shave and after-shave 
products) 
"natural" cosmetic products. 
and various products which protect the skin or mucous membrane and keep them in good 
condition,  such  as  sun  creams,  baby  creams,  certain  anti-dandruff  shampoos,  wart 
removers, moisteners, deodorants, cariostatic toothpastes, etc. 
'The coacept or risk to bum• bealdl is 8110ciated wida intiiiUite (skiD, muco• melllbnae) 
mel continued contlld wida 1hese  IJI'Oducts  mel with chronic e:s.potUR  (  coDSeqUeace  of 
10 frequent and usually daily usage, extending over a major part of a penon's life) of all 
cateaories of consumen. 
Consequently,  apart  from  the  immediate  and  invisible  adverse  effects  of cutaneous 
intolerance, we cannot a priori rule out systemic efTeds involving action via the  blood 
stream after percutaneous absorption or lona-tenn systemic or cutaneous effects. 
The potential systemic risk justifies the performance of prospective sub-chronic toxicity 
and mutagenicity tests and, possibly, tests of toxicokinetics, teratogenesis/reproduction, 
additional genetic toxicology and carcinogenesis tests for certain ingredients, as well  as 
calculating a safety margin for human use. 
D.  'DIE ACI'ORS 
The actors responsible for promoting research, development and validation of alternative 
methods are active at Community and international level, viz. the Commission, European 
industry and international relations. 
1  mE COMMISSION 
Several  Commission  departments  deal  with  animal  tests  and  work  together  towards 
realising the three Rs - replacement, reduction, refinement. 
The Commission subsidises all or part of  several "ad hoc" studies conducted by university 
and industrial laboratories and by scientific companies. 
1.1  The Consumer Policy Service (CPS) 
The Consumer Policy Service,  whose  remit includes cosmetic products,  has close and 
regular links with the Directorates-General for Industry (DG III), the Environment (DG 
XI), Agriculture (DG VI), Employment, Industrial Relations and Social Affairs (DG V) 
and the Joint Research Centre (DG XII). 
The  CPS  manages  the  Cosmetic  Products  Directive  and  is  advised  by  the  Scientific 
Committee  on  Cosmetology  (SCC).  The  SCC  is  one  of the  Commission's  advisory 
committees and was created by Commission decision of 19 December 1977·. Members 
include experts in the field of toxicology, pharmacology, biology and dermatology, and 
it is responsible for evaluating the safety of  cosmetic products for human use and notably 
evaluating  the  toxicity  of cosmetic  ingredients  listed  in  the  annexes  to  Directive 
76/768/EEC. 
The CPS has requested the  SCC  to  issue,  before  1 January  1997, the final  date for  a 
possible report on the application of the provisions of Directive 93/35/EEC, a scientific 
opinion on the applicability of validated alternative methods in the process of evaluatin& 
the safety of cosmetic products  . 
•  OJ 13, 17.1.1978, page 24 
II In the context of this mandate, a subgroup on guidelines and alternative methods was set 
up  by  the sec and is  responsible for: 
actively  monitoring  the  validation  studies  coordinated  by  ECVAM  and  other 
centres 
adopting methods validated by  the OECD 
liaising with  experts from  industry  involving dialogue  at  the  highest scientific 
level in order to learn more about the basic biochemical mechanisms of in vitro 
methods and obtaining a handle to interpret the results, with a view to preparing 
an objective and solidly reasoned opinion addressed to  the Commission 
assessing the applicability of  validated alternative methods to evaluating the safety 
of cosmetic ingredients. 
updating the guidelines for evaluating the safety of cosmetic ingredients. 
1.2  ECVAM 
The European Centre for the Validation of Alternative Methods (ECV AM) was set up by 
the Commission under Decision EC/90/67. It is attached to the Joint Research Centre at 
lspra and uses its technical and scientific infrastructure. Its task is: 
to coordinate the validation of alternative methods at Community level 
to pool information 
to  develop and manage a database on AM 
to encourage dialogue between all operators concerned. 
In implementing the sixth amendment to the Cosmetic Products Directive, ECV  AM works 
together  with  the  CPS,  the  European  cosmetic  industry  and  research  laboratories 
specialised in the field of alternative methods. 
The CPS and ECV AM otganised a joint workshop at lspra ( 11-13 April 1994) on the use 
of AM in implementing the sixth amendment to Directive 76/768/EEC. This workshop 
made it possible to  focus  more clearly on the problems and to  identify areas in  which 
action was desirable. 
l  EUROPEAN INDUSTRY 
European industry devoted ECU 25  million during 1993 to meet the challenge presented 
by the sixth amendment to the Cosmetics Directive. It played a major role in the research 
and development of in vitro methods which made it possible to reduce or avoid the use 
of animals. 
In  1992 the  Liaison  Committee of European  Associations of the  Perfume,  Cosmetics 
Products  and  Toiletries  Industries  (COLIPA)  set  up  the  Steering  Committee  on 
Alternatives to  Animal Testing (SCAAT). 
SCAAT members include heads of  R&D at several European cosmetics firms. It provides 
guidance to the cosmetics industry with a view to replacing animal tests by validated .and 
approved  alternative  methods.  In  this  connection  it  supervi~ and  reviews  COLIPA 
12 validation  studies  and  coordinates  the  validation  work  of  the  cosmetics  industry 
throughout the world. SCAA  T works together with all scientific, industrial and regulatory 
agencies concerned with the development, validation and implementation of alternative 
methods. 
3  INTERNATIONAL RELATIONS 
Europe,  America and Japan have  been  working together for  some time as  a  result of 
initiatives by  CO  LIP  A. 
Since 1981  the CFTA (Cosmetics, Toiletry and Fragrance Association) has supported the 
establishment of a Centre for Alternatives to Animal Tests (CAAT) at the John Hopkins 
University (USA). 
COLIPA works together with CTFA, ECVAM and JCLA (Japanese Cosmetic Industry 
Association),  notably in  regard to  programmes  to  validate alternative  methods  to  the 
Draize eye irritation test. 
E.  1HE IN rnA  TIVES 
Several  initiatives  have  been  launched  in  the  European  Union  by  CPS/SCC, 
JRCIECV  AM,  CO  LIP  A/SCAA  T  as  well  as  in  the  United  States  and  Japan,  and 
instruments to develop and validate alternative methods have been implemented. 
1  CPS/SCC 
The purpose of this report, drawn up  by  the Consumer Policy Service, is to inform the 
European Parliament and Council, of the state of progress of alternative methods and to 
stimulate  research  with  a  view  to  achieving  the  objectives  enshrined  in  Directive 
93/35/EEC. 
The sec subgroup on alternative methods/guidelines organised two working meetings in 
July and October 1994 concerning the progress of the validation studies coordinated by 
SCAAT/COLIPA. 
l  JRCJE<:.V AM 
ECV  AM draws on the two databases GALILEO OAT  A BANK and INVITTOX. 
GALILEO  DATA  BANK  (GOB),  a  database  subsidised  by  CPS/DG  XI  and 
JRCIECV  AM, has been set up at the University of Pisa to collect and evaluate the results 
of in vitro toxicity tests. 
GALILEO has already evaluated 21  000 toxicity tests results conducted using alternative 
methods and other methods. 
INVITTOX,  financed  by  FRAME (Fund for  the  Replacement of Animals in  Medical 
Experiments) and the EC, is located at Nottingham and its main function is to produce 
13 protocols  of in  vitro  tests.  Up  to  now  INVITTOX  has  collected  approximately  100 
protocols.  An  exhaustive list of these protocols is provided in  annex 2. 
Of the six ongoing prevalidation/validation studies involving ECV AM,  those of direct 
interest to  evaluating cosmetic products safety are: 
an  ECIUK study on in  vitro/eye irritation 
a CO LIP  AlEC study on in  vitro photoirritation/phototoxicity 
a European/US study on in vitro skin corrosion. 
Among the subjects of  the 1  5 working meetings scheduled by ECV AM in  1993/94, those 
of direct relevance to evaluating the safety of cosmetic products are: 
in vitro phototoxicity 
in  vitro teratogenicity 
in vitro acute toxicity 
in vitro cutaneous penetration 
the challenge of the sixth  amendment to  the  Cosmetics Directive (11-13  April 
1994). 
The specific  responsibilities of ECV AM  (coordinating the validation of AM)  and  the 
Scientific Committee on Cosmetology (evaluating the safety of cosmetic products) were 
defined at the CPSIECV  AM workshop of 11-13  April  1994. 
However, no definitive agreement was reached as regards the use of alternative methods 
in  implementing the sixth amendment to  Directive 76/768/EEC. 
3  COLIPA/SCAAT 
SCAAT liaises directly with the Commission and Member States. 
The European cosmetics industry has been involved for a number of years in numerous 
programmes  for  developing  and  optimising  alternative  methods.  Such  methods  have 
already  been applied in  industrial  research  during pilot phases  in  connection  with  the 
development of new substances and are also used to evaluate finished products. 
Two  validation  programmes have  been  initiated  by  SCAAT  (photoirritation  and  eye 
irritation) and  working parties have been given  the  task of developing  methods in the 
fields of skin tolerance in man and percutaneous absorption. 
4  USA/JAPAN 
CFTA,  in  the  context of its  programme for  evaluating  analytical  methodologies,  and 
JCLA,  in  cooperation  with  the  Japanese  government,  are  participating  in  the  new 
programme for validating alternative methods to the Draize eye irritation test, coordinated 
by COLIPA. 
14 The Food and Drug Administration encourages the development of alternative methods 
but poina out Chat  no  alternative  test ba yet been  accepted  by  die  entire  scientific 
community to  replace die Dnize test and concludes that it is unlikely that animal tests 
can be completely dispensed with in the near future. 
F.  STATE OF PLAY 
The state of play may be summarised as follows: 
1  IN VITRO ME'IBODS aJRREN'ILY BEING DEVELOPED AND VALIDATED 
Photoirritationlphototoxicity: validation (COLIPAIDG XIIECVAM) 
There are no in vivo phototoxicity tests in the OECD guidelines. 
The  first  experimental  phase,  focusing  on  biochemical  tests  and  a  standardised 
cytotoxicity test, has been concluded. 
The  results  make  it  possible  to  identify  a  limiting  factor  distinguishing  phototoxic 
substances from non-phototoxic substances. 
Correlation with in vivo data in the literature (man/animal) is excellent. 
The second phase comprises a validation study of two cell tests and a prevalidation study 
of eight other tests. The results of the validation involving a blind study coordinated by 
ECV  AM are due in late 1994. 
Percutaneous absorption:  prevalidation (COLIPAIECV  AM) 
A standardised Franz cell diffusion method using the freshly excised, shaved and thinned 
skin  of the  pig  is  currently  being  practised  in  numerous  laboratories  on  cosmetic 
ingredients and on finished products (particulary on hair dyes). 
The method was proposed to the OECD. It has been validated through reproducible intra-
and  interlaboratory  results  showing  a  good  in  vitro/in  vivo  correlation  for  several 
substances. It can replace in vivo cutaneous penetration tests but tells us nothing about 
the metabolism and toxicokinetics. 
This autumn SCAA  T will examine ongoing experimental work on the  use of standard 
protocols for specific groups of substances tested. 
Eye irritation: validation (COLIPA) 
This programme supplements the international validation exercise on alternative methods 
to the Draize eye irritation test for classifying and labelling chemical substances (EC 
DG XI/UK Home Office), illustrating the difficulties of validation studies. 
15 The purpose is  to  validate  l 0 in  vitro tests on a sample of 23  cosmetic ingredients and 
32 formulations chosen to  cover a range of potential irritants. 
The experimental phase ends in July 1995. The results of  the final report will be available 
in September 1995. 
Although  sampling is not enough  to  cover the  entire cosmetic  universe  (in  particular, 
ingredients covered  by  Directive  761768/EEC),  the study  should cast  light on  certain 
classes of products. 
Skin sensitisation:  development (DG XII -BRIDGE) 
It is too early to develop a validation programme, because of the complex mechanisms 
of the  sensitisation  process.  A  project  for  developing  an  in  vitro  test  for  detecting 
sensitising substances was launched in  1991  (DG XII). 
A cute toxicity: development (EC/FRAME) 
The methods developed on cell cultures are useful for determining test doses for tests on 
the entire animal and contribute to reducing the number of animals tested.  Most of the 
biological  consequences are  quantitative for  a given group of substances and make it 
possible to posit a lowest effective dose (LED). No conclusive results have been obtained 
from the validation programmes developed to date. 
Skin irritation:  development (UK/France/Germany/USAIEVCAM) 
In  vitro  approaches,  using  cell  lines  of skin  tissue  and  abiotic  systems,  have  been 
developed with  mixed success.  Adequate evaluation  depends on the availability of an 
extensive in vitro database and a database on in vivo irritation. 
In view of the cummt state of research, and the difficulty o~  validation exercises, in vitro 
methods cannot yet replace RSD on the live animal. 
AdeqiUUe validation of the methods is  the key to  their legal acceptance. 
Difficulties involved in validation studies 
Validation studies are costly and time-consuming. 
As regards alternative in vitro tests, it is difficult to draw conclusions on the performance 
of  the individual tests. The performance of  the test systems varies with the substances and 
the groups of products tested and it is impossible to extrapolate the results of  a validation 
exercise to all types of substances and products. 
'The  mechanistic  nature  of in vitro  Rsm  effectively  makes it essential  to  identify  and 
validaR an optimised batte.y of supplementaly tests to  mimic an in vivo toxic effect. 
'The  numerous validation exercises asociaRd with in vitro eye imtation tests illustrate 
these problems. 
16 A  survey  has  been  conducted  of a  total  of 31  studies  using  30  protocols  with  41 
biological  consequences  in  tests  involving  between  10  and  465  substanc~s  and 
formulations. 
Of these studies, the most recent was developed by EC - DG XI/UK - Home Office and 
involves 37laboratories, 60 test substances and nine protocols at a total cost of 1 361  000 
ecus. 
The nine tests were selected because they satisfied the following criteria: 
specific, well-defmed and supplementary objectives 
developed, standardised protocols, appropriately documented 
promising results in one or several interlaboratory studies 
the possibility of being used on a routine basis. 
The substances  to  be tested were selected  to  represent  different  ranges  of chemical 
functions, irritant poteritials, physical states and physico-chemical properties. 
The 3  7 laboratories selected on the basis of their experience are located in nine countries 
including the USA and Japan. 
An independent agency, BIBRA, has been commissioned to  collect and distribute the 
substances to be tested and to receive the results. 
The  tests  will  be  evaluated  to  determine  their  performance,  individually  and  in 
combination. 
The results will be published in January 1995 and ECV  AM will organise a meeting with 
a view to a final discussion in September 1995. 
l  LEGAL ACCEPfANCE: OECD 
A cute toxicity,  oral route 
Two  methods  contribute to  reducing  the  nu~ber of test animals  and  the  sufferings 
inflicted on them as compared with the conventional method described in the OECD 
guidelines 401  (see page 5). 
Fixed dose method - OECD 410 
The in vivo fixed dose method proposed by the British Toxicology Society restricting the 
number of test animals and reducing animal suffering was  accepted by the OECD (3] 
after an international validation study showed that it was scientifically valid for the values 
LD < 25  mglkg, 25 to 200 mglkg, 200 to 2000 mg/kg and > 2000 mglkg. It has been 
approved with-the preliminary screening test which provides information on the dose to 
be applied in the main study (OECD, 7.1.1992). 
17 .'•, ., 
Acute tos.ic  class method (ACf) 
ACT is based on a step by step procedure, using the minimum number of animals, and 
provides sufficient information on the acute toxicity of the test substance for it to  be 
classified in  accordance with the current schedules.  Although the animal's death is the 
main  biological  consequence,  this  procedure  reduces the number of test animals and 
alleviates suffering.  ACT is in  the final  acceptance stage after international  validation 
under the patronage of the OECD. 
Slcin  sensitisation 
LLNA  and MEST tesa 
The local  lymphatic test (LLNA) and the mouse ear oedema test (MEST) can identify 
moderate to strong sensitising potential. 
OECD recommends using these tests as a first stage in evaluating a sensitising potential. 
If a positive result is obtained in one of these tests, it is not necessary to continue with 
in vivo tests. 
Legal tJCceptiiiU:e of  in vitro IMihotls 
The  domains  in  which  in  vitro  methods  have  been  legally  accepted  are  essentially 
restricted to mutagenicity/genotoxicity data (basic tests) and screening tests with a view 
to studying severe irritation of the skin and eyes. 
Mutagenicitylgenotoxicity 
On  26  May  1994  the  OECD  distributed  a  draft  review  of  eight  short-term 
mutagenicity/genotoxicity tests, of which three in vitro: 
back muation test on bacteria 
chromosome abe1111tion test on in vitro mammal cells 
aene muation test on in vitm mammal cells. 
The combination of these three tests makes it possible to  identify  mutagenic potential 
and/or carcinogenic potential via a genotoxic mechanism. 
Use of in vivo tests can be limited to certain cases, to verify whether an activity observed 
in vitro is also expressed in vivo. 
Slcin and eye irritation 
The OECD guidelines, revised in 1992, recommend adoption of a hierarchical approach 
to eliminate severe irritants to the skin and eyes by considering the physico-chemical 
properties, pH values and data obtained from in vitro tests. The latter are not defined. 
18 Since then  animals have only  been used to  prove the absence of irritation or to  define 
light to  moderate potential. 
G.  ANIMAL TFSTS: STATISTICS 
I.  It is not yet possible to provide a realistic estimaae of the number of animals used 
to  test the toxicity of cosmetic ingredients, as  required by  Article 4 of Directive 
93/35/EEC. 
'The  data available  through  Member States  mainly  concern  finished  cosmetic 
products, including body hygiene products. 
On  the basis of partial  information communicated by  the  Member States under 
Articles  13  and 26 of Directive 86/609/EEC on the number of animals used for 
experimental purposes or other scientific purposes during 1991, no monkeys, cats 
or dogs were used to test cosmetics, and the numbers of rodents and rabbits used 
to test cosmetics and body hygiene products, compared with the total number of 
animals of the same species used in toxicity tests in  the field of human, animal 
and environmental protection, are: 
248 to  25  994 in the Netherlands 
2 028 to  19 468 in Spain 
22  880 to 89 620 in  France 
3 082 to 171  530 in the United Kingdom. 
However, these data may not be as revealing as one might think, since: 
toxicity tests for American and Japanese companies are mainly conducted 
in France, the United Kingdom and Germany 
most  of the  tests  were  performed  on  finished  products  or for  internal 
monitoring purposes 
the statistical data furnished by  the Member States are incomplete. 
2.  On the other band, an estimated 38 900 laboratocy animals were used to  test the 
43  cosmetic  ineredients  evai118Rd  in  1993  by  the  Scientific  Committee  on 
Cosmetology; these  tesCs  last on average ten yean; this  number comsponds to 
approiii!UlRiy 900 animals per cosmetic ingredient or less than 100 animals per 
ingredient per year. 
19 Number of laboratory animals used to evaluate the safety of cosmetic ingredients, 
calculated on the basis of the dossiers examined by the Scientific Committee on 
Cosmetology in  1993 
43  cosmetic  Rats  Mice  Guinea  Rabbits  Hamsters  Total 
ingredients  pigs 
5 preservatives  21  000  14  500  2 600  700  100  38 900 
8 UV filters 
30 hair dyes 
The studies were conducted in Europe, except for most of the long-term carcinogenicity 
studies (which require a greater number of animals) developed in the USA under the 
National Toxicology Program. 
The figure of 38 900 relates to the number of rodents and rabbits used to test cosmetic 
i1111Mien11  and is extremely low by comparison with the total number of animals used 
in  all sectors (11  790 485) (Directive 86/609/EEC). 
20 H.  PROGRESS: STA ll.JS - OCTOBER 1994 
CLASSICAL  ALTERNATIVE METHODS: toxic effect  Coordination/  End of Study  Screening and strategy 
IN VIVO  Support/  of the three Rs  I 
METHODS  Cooperation 
I 
OECD 406 (1992)  D  -Cutaneous leDiids8tion  DG XII (BRIDGE)  1994  Screening 
I 
E  Predicative in vitro test to detect sensitising components 
v 
UK I France i Germany  OECD 404 (1992)  E  - Skin irritation  1994  Screenin8 I Reduction 
L  In vitro prevalidation tests of cutaneous agressiveness  USA/ECVAM 
0  ( 3 tests, 7 laboratories, 50 test materials) 
OECD 401  (1987)  p  - Acute toxicity  EC /FRAME  Screening I Reduction 
M  Utilisation of  a battery of in vitro tests to predict acute lethal potential 
E 
OECD (draft 1994)  N  - Percutmeoas llbsorption  COLIPA I ECV  AM  Replacement 
T  Pnwalidation of standardised in vitro protocols for specific groups of substances 
- Pbotomabgenicity  COLIPA  Screening 
OECD 405 (1987)  v  - Eye irritation 
A 
L  1) Alternatives of AM to the Draize test with a view to classifying and labelling  EC DG XI/ UK Home  September 1994  Replacement I 
' 
I  chemical substances ( 9 tests, 37 laboratories, 60 test materials)  Office  Reduction 
I  D 
A  2) Validation of AM to Draize tests on a sample of cosmetic products (10 tests,  COLIPA  July 1995  Replacement I 
T  55 test materials)  Reduction 
I 
0  - Pbototo:licity/pbotoinitadon  EC DG XI/ COLIPA I  end 1994  Replacement 
N  Validation by blind test (second phase), (2 tests, 32 test materials)  ECVAM 
LEGAL ACCEYI'ANCE  - Acute toxicity  Reduction I Refming 
-OECD  Fixed dose  OECD 420 (1992) 
ATC  OECD (draft 1994) 
- Mlagenicity/genotoxidty  OECD 471. 472, 473, 476 (draft 1994)  Screening I Refining 
21 L  CONCLUSIONS 
Since the adoption of Directive 93/35/EEC, an  enormous amount of work has been put 
in  by  the  Commission  and the European  cosmetics  industry,  which  had already  been 
working  towards  this  end  for  a  number  of years,  and  close  cooperation  has  been 
established with the USA and Japan with an  eye to improving animal welfare. 
The state of play in October 1994 is summarised in Table H. It should be noted, however, 
that: 
A.  Up  to  now, no  conclusions can  be drawn from  the numerous validation studies 
conducted  in  1993  which  would  have  an  immediate  influence  on  the 
implementaUon of the sb.dl amendment to  Directive 761768/EEC. 
To  ensure consumer protection, Directive 76/768/EEC and its annexes prohibits 
the use of  toxic substances in finished cosmetic products, lays down specific limits 
for the use of certain ingredients and provides for  a system of positive lists for 
certain categories of  ingredients particularly liable to .imperil human health; in the 
context of positive lists, only those ingredients listed may be used.  Before being 
included in the·annexes to the Directive, the substances and ingredients considered 
must first be analysed by the sec in regard to their potential toxic effects. 
The results obtained in the development and validation ·of batteries of in vitro eye 
irritation tests concern specific chemical families and certain groups of finished 
products; there is no conclusive evidence that these results can be extrapolated to 
the  evaluation  of  ingredients  belonging  to  different  structural  classes  and 
functional groups - notably to the ingredients likely to be included in the positive 
lists, viz.  preservatives, colouring agents and UV filters·(hair dyes). 
Barring some exceptions, the cosmetic ingredients belonging to these categories 
and  certain cosmetologically "active"  substances have not been included in  the 
validation studies.  The 57 studies covered include only  15  of the 723  cosmetic 
ingredients so  far listed in  the annexes to Directive 76/768/EEC. 
B.  The  interesting but limited findings to  daR  mean that lllimal models cannot be 
replaced, thouah they  can contribu1e to  reducing the number of animals used in 
subsequent studies. 
C.  COLIPA  envisqes  usin&  clinical  data  rather  than  animal  tests  to  test  skin 
irritation potential in finished products after elimination of the severe irritants on 
the basis of an  initial and suitable in vitro approach. 
D.  Application  of in  vitro  methods  to  evaluating  the  safety  of "house"  products 
carried out by  leading European firms clearly shows the different approaches in 
regard to ingredients and finished products. 
22 1be findings. to cia shows that it is too early to  replace animal methods by aHemative 
methods in testing the ingrediena, aUho01b tbe finished produces c•  be generally tested 
in vitro thanks to existing knowledge of toxicity data concemi111  tbe ingrediena. 
It is  interesting to  note  that the  STOA  report
1  (Scientific and  Technological  Options 
Assessment) drawn up on the basis of a proposal by the Environment Committee of the 
European Parliament comes to practically the same conclusions. This study, intended to 
assess the  possibility  of totally  eliminating the  use of laboratory  animals  in  cosmetic 
product toxicity tests, describes the situation clearly. It is divided into two sections: the 
first, based on a questionnaire drawn up by STOA, analyses industry practice in Europe, 
the USA and Japan, while the second reviews the literature relating to animal tests used 
for cosmetic products and on recently developed alternative methods. 
With regard to the future, the situation may be summarised as follows: 
1  mE OU'IU)()K 
One can reasonably hope that: 
1.1  In vitro  alternative  methods will be able to  replace miiiUII  models in the near 
future, while affonli111  consumen a level of protecdon equal to  that associated 
with animal tesa, in tbe fields of: 
eye irritation 
percutaneous ablorpdon 
muialenicity (basic tesa) 
pbototo:dcity/pbotoiniadon. 
With  the  exception  of  the  mutagenicity  tests  already  adopted,  their  legal 
accepCance cannot be assuiH undl tbe difficuldes •d  unknowns in the validation 
•d  evaluation exercises refened to earlier on have been removed. 
1.2  Finished products can  rapidly  be tested exclusively  in  vitro thanks to  existing 
knowledge on the toxicity of ingredients. 
2  FORESEEABLE DIFFICULTIES 
Research on alternative methodologies is considerably limited in toxicity studies, which 
are indispensable for evaluating the systemic risk.  This is because of the difficulty of 
integrating in vivo or ex vivo the numerous complex interfering biochemical mechanisms 
which characterise life processes in the higher animal and in man. 
Given the ctllftnt scme of the art, it is unlikely that mimal tesa c•  be totally replaced 
in: 
• An assessment of cwnmt scientific developments  in  the  field  of non-animal  testing  for  cosmetic 
products"  Final report, 98 pp.  Ed.  V.  Zuang, 1994, PE 164-906. 
23 studies of acute lethal toxicity  . 
studies of chronic and subchronic  to~icity, whose objective is 
to determine the toxicological profile of the substance studied and the no adverse 
effect level 
toxicokinetics studies 
carcinogenesis studies 
reproduction/teratogenesis studies. 
sensitisation studies 
However, in vitro  studies developed in tbese  domains give us  a  better picture of the 
action  mechanisms relating to  a metabolic process in  man or in the animal, or a toxic 
effect identified in  animals, and contribute to reducina the number of test animals. 
3  PROPOSAlS FOR 111E FU11JRE 
In the context of implementing Directive 93/35/EEC it would be important to undertake 
the following future measures, the need for which was stressed at the joint ECV  AM/CPS 
workshop: 
Verify whether studies currently being developed and validated can be applied to 
a greater number of different substances and, notably, ingredients regulated by the 
Cosmetics Products Directive 
Select, from among the cosmetic ingredients whose safety has been evaluated by 
the sec, a group of substances whose in vivo toxicity data are pertinent to an in 
vitro/in vivo correlation exercise 
Optimise  exploitation  of databases  of tests  and  implement  an  adequate  and 
coordinated system  for  providing information by  creating a  cosmetic products 
database. 
The Commission is  convinced that research  into alternative methodologies intended to 
replace  live animals will  continue in  parallel  with  methods to  reduce animal suffering 
and/or· contributing to reducing the number of test animals and that ECV  AM will be able 
to  expedite the process of legal adoption of methods validated by the OECD. 
It hopes that this report will stimulate all operators concerned and encourage the adoption 
of alternative methods in  a number of areas. 
24 Annexe I 
Validation: the Amden principles 
I.  The purpose of a validation study should be fully defined, particularly in relation to the level  of 
assessment (toxic potential,  toxic  potency,  hazard  or risk),  and  in  relation  to  the type of test 
required  (screening,  adjunct  or  replacement),  the  type  of toxicity  to  be  evaluated,  and  the 
chemical spectrum of interest. 
2.  Tests should only be considered for inclusion in validation studies, if the specific purposes for 
which they have been developed are well defined and are consistent with the overall objectives 
of the validation study. 
3.  Tests must have been adequately developed, standardised and documented and a need for them 
in relation to the availability of other tests must exist, before they should be considered eligible 
for validation. 
4.  Various sets of reference chemicals are required for the validation process, namely: 
Reference set 1:  a calibration set for use in test development and interlaboratory assessment; 
Reference set 2:  an  interlaboratory  reference  set  for  use  in  the  blind  trial  phase  of 
interlaboratory assessment; 
Reference set 3:  an  interlaboratory  reference  set  for  use  in  the  definitive  phase  of 
interlaboratory assessment, and 
Reference set 4:  a database reference set for use in test database development. 
S.  The four sets of chemicals selected for validation studies should fonn the basis of a Chemical 
Reference bank, to facilitate the provision of chemicals and reference data for the validation of 
tests  internationally.  The  establishment of an  International  Chemicals  Reference  Bank  is  a 
matter  of urgency.  The  bank  should  provide  open-access  listings  of scientifically-selected 
chemials, backed by toxicological  data reviews,  safety advice and a source of chemicals of 
known purity and stability. 
6.  Any  particular test  should  be  validated  against  the  most  appropriate  collection  of reference 
chemicals, bearing in mind the specific purpose for which the test is proposed. 
7.  The toxicological classification of reference chemicals in terms of their toxic properties should 
be carried out by a panel of expert toxicologists, taking into account all  the available relevant 
data.  Final classifications should be fully documented with respect to both acceptable data and 
criteria, and the statistical evaluation procedure used. 
8.  When classifying reference chemicals for use in validation studies, consideration should be given 
to  the  numerous  factors  which  affect  the  generation  and  quality  of reference  data  and  the 
expression and evaluation of toxicity in the animal  investigated. 
9.  It  is  highly  desirable  that  industry  should  play  an  active  role  in  validation,  specifically  by 
supplying data not generally available to the scientific community at this time. 
10.  Schemes currently being developed for assessing human toxicology data and making them more 
readily available to validation studies, should be welcomed and supported. 
11.  Information toxicologists should be encouraged to investigate ways of  integrating the information 
obtained  in  experimental  toxicology,  human  toxicology  and  veterinary  toxicology,  and 
incorporating  this  data  into  the  validation  process  for  reference  classification  of chemicals, 
whenever this feasible. 
12.  Wherever it is desirable and  practicable,  methods for the collection,  collation,  evaluation and 
expression of experimental, human and veterinary toxicological data should be standardised in 
ways which have been agreed upon by, and are acceptable to,  the toxicological community as 
a whole. Annex  II 
LIST  OF  INVITTOX  METHODS 
- RABBIT  ARTICULAR  CHONDROCYTE  FUNCTIONAL  TOXICITY  TEST 
- SIRC  CYTOTOXICITY  TEST 
- V79  CYTOTOXICITY  TEST  FOR  MEMBRANE  DAMAGE 
- LS-L929  CYTOTOXICITY  TEST 
- RED  BLOOD  CELL  TEST  SYSTEM 
- AUTOMATED  IN  VITRO  DERMAL  ABSORPTION  (AIDA)  PROCEDURE 
- QUANTITATIVE  VIDEO  MICROSCOPY  OF  INTRACELLULAR  MOTION  AND 
MITOCHONDRIA  - SPECIFIC  FLUORESCENCE 
- LLC-RK1  CELL  SCREENING  TEST  FOR  NEPHROTOXICITY 
- HEp-2  CYTOTOXICITY  TEST  FOR  IMPLANT  MATERIALS 
- H-4-II-E  RAT  HEPATOMA  CELL  BIOASSAY 
- LUNG  CELL  ASSAY 
- HET-CAM  TEST 
- THE  FRAME  MODIFIED  PHOTOTOXICITY  ASSAY  USING  HUMAN 
KERATINOCYTE  MONOLAYER  CULTURES 
- FIXED  DOSE  PROCEDURE  FOR  THE  FLUORESCEIN  LEAKAGE  TEST 
- THE  FRAME  CYTOTOXICITY  TEST  (KENACID  BLUE) 
- THE  POLLEN  TUBE  GROWTH  TEST  (PTG-TEST) 
- HEN'S  EGG  TEST  - YOLK-SAC  BLOOD  VESSEL  ASSAY 
- HUMAN  AND  BOVINE  LENS  EPITHELIAL  CULTURE 
- UV  ABSORPTION  AS  AN  APPROXIMATION  FOR  CELL  NUMBER 
- EYE  LENS  ORGAN  CULTURE 
- AN  IN  VITRO  MODEL  FOR  STUDIES  OF  PROSTAGLANDIN  H SYNTHASE 
(PHS)-MEDIATED 
- GENOTOXICITY  OF  XENOBIOTICS 
- SCREENING  SYSTEM  OF  PROMOTERS  USING  RAS  TRANSFECTED  BALB  3T3 
CLONE  (BHAS  42) 
- THE  NEUTRAL  RED  CYTOTOXICITY  ASSAY 
- LUCIFER  YELLOW  INTERCELLULAR  EXCHANGE  ASSAY  FOR  TUMOUR 
PROMOTERS 
- SERUM-FREE  LIVER  MITOGEN  TEST 
- EMBRYOTOXICITY  TESTING  USING  A WHOLE-EMBRYO  CULTURE  (W.E.C.) 
PROCEDURE 
- PRIMARY  HUMAN  HEPATOCYTE  CULTURES  FROM  SMALL  SURGICAL 
BIOPSIES 
- THE  ISOLATED  PIG-EAR  SKIN  PERMEATION  MODEL 
- THE  FLUORESCEIN  LEAKAGE  TEST 
- RAT  WHOLE  EMBRYO  CULTURE 
- TWO-COMPARTMENT  HUMAN  TISSUE  CYTOTOXICITY  TEST 
- TETRAHYMENA  THERMOPHILA  CHEMOSENSORY  RESPONSE 
- TETRAHYMENA  PROLIFERATION  RATE  AND  MAXIMAL  DENSITY 
- NEUTRAL.RED  BIOASSAY  USING  BALB/c3T3  CELLS 
- BLIND  ·TRIAL  PROTOCOL 
- GAP  JUNCTIONAL  INTERCELLULAR  COMMUNICATION  ASSAY 
- TETRAHYMENA  ASSAY  FOR  MEMBRANE-STABILISING  ACTIVITY 
- THE  COMPLEMENT  PHOTOACTIVATION  ASSAY 
- 3T3  NRU  PHOTOTOXICITY  ASSAY 
- ATS  SKIN2  ZK  1350  PHOTOTOXICITY  ASSAY 
- SOLATEX-PI  PHOTOTOXICITY  TEST 
- CHICKEN  ENUCLEATED  EYE  TEST  (CEET) 
- THE  RABBIT  ENUCLEATED  EYE  TEST 
- TRANS-EPITHELIAL  PERMEABILITY  (TEP)  ASSAY - ARACHIDONIC  ACID  RELEASE  AS  A MEASURE  OF  MEMBRANE  TOXICITY 
- PHOTOBINDING  TO  PROTEIN 
- PHOTOSENSITIZED  OXIDATION  OF  HISTIDINE 
- SPONTANEAOUSLY  CONTRACTING  CULTURED  RAT  SKELETAL  MUSCLE 
CELLS  FOR  TESTING  TOXIC  EFFECTS  ON  EXCITABLE  TISSUES 
- CULTURE  OF  HUMAN  CUMULUS  GRANULOSA  CELLS 
- METHYL  GLUCOSE  UPTAKE  IN  PRIMARY  CULTURES  OF  PROXIMAL 
TUBULAR  CELLS 
- METHYL  GLUCOSE  UPTAKE  IN  ISOLATED  PROXIMAL  TUBULAR  CELLS 
- ISOLATION  OF  RAT  TYPE  II  ALVEOLAR  EPITHELIAL  CELLS 
- POLYMORPHONUCLEAR  LEUKOCYTES  LOCOMOTION 
- CYTOSKELETAL  ALTERATIONS  AS  A  PARAMETER  FOR  ASSESSMENT  OF 
TOXICITY 
- THE  AMES  TEST. 
- MODEL  CAVITY  METHOD 
- DNA  BINDING  STUDIES  FOR  ALKYLATING  COMPOUNDS  USING  ISOLATED 
PERFUSED  RAT  LIVER 
- DNA  BINDING  IN  BACTERIA 
- RED  BLOOD  CELL  LYSIS  AND  PROTEIN  DENATURATION 
- THE  BOVINE  CORNEAL  OPACITY  AND  PERMEABILITY  ASSAY 
- THE  SILICON  MICROPHYSIOMETER  TOXICITY  TEST 
- THE  HEN'S  EGG  TEST  ON  THE  CHORIOALLANTOIC  MEMBRANE  (HET-CAM) 
BIS 
- THE  HEN'S  EGG  TEST  ON  THE  CHORIOALLANTOIC  MEMBRANE  (HET-CAM) 
- BOVINE  ISOLATED  CORNEA  TEST 
- RABBIT  ISOLATED  TERMINAL  ILEUM 
- REACTIVE  METABOLITE  FORMATION  BY  FORTIFIED  LIVER  MICROSOMES 
- WHOLE  RAT  BRAIN  REAGGREGATE  CULTURE 
- HEPATOMA  CELL  CULTURES  AS  IN  VITRO  MODELS  FOR  HEPATOTOXICITY 
- HEL  30  CYTOTOXICITY  TEST 
- CYTOTOXICITY  AND  GENOTOXICITY  IN  PRIMARY  CULTURES  OF  HUMAN 
HEPATOCYTES 
- MTT  ASSAY 
- UNSCHEDULED  DNA  SYNTHESIS  IN  HEPATOCYTE  CULTURES 
- ASSESSED  BY  THE  NUCLEI  PROCEDURE 
- ALKALINE  UNWINDING  GENOTIXICITY  TEST 
- ISOLATION  OF  RAT  HEPATOCYTES 
- BOVINE  SPERMATOZOA  CYTOTOXICITY  TEST 
- TETRAHYMENA  THERMOPHILA  OCULAR  IRRITANCY  TEST 
- RAT  HEPATOCYTE  FLOW  CYTOMETRIC  CYTOTOXICITY  TEST 
- LASER  DIFFRACTION  MEASUREMENT  OF  TUMOR  SPHEROIDS 
- THE  ZEIN  TEST 
- HUMAN  SKIN  FIBROBLAST/COLLAGEN  LATTICE  CYTOTOXICITY  TEST 
- HUMAN  OESOPHAGEAL  CULTURE 
- HUMAN  THYROID  CULTURE 
- AGAROSE  OVERLAY  ASSAY 
- DUST  TOXICITY  IN  RAT  ALVEOLAR  MACROPHAGE  CULTURES 
- YEAST  GROWTH  RATE  CYTOTOXICITY  TEST 
- YEAST  PLASMA  MEMBRANE  H+-ATPASE  TOXICITY  TEST 
- CHINESE  HAMSTER  OVARY  CELL  NA+/K+  - ATPASE  TEST 
- CHINESE  HAMSTER  OVARY  (CHO)  CELL  PROLIFERATION  TEST 
- ISOLATED  RAT  GLOMERULI  AND  PROXIMAL  TUBULES 
- HUMAN  LYMPHOCYTE  CYTOTOXICITY  ASSAY 
- THE  ISOLATION  AND  CULTURE  OF  RAT  HEPATIC  CELLS 
- THE  USE  OF  MEMBRANE  PERMEABILITY  AS  A MEASURE  OF 
CYTOTOXICITY  IN  PERFUSED  CELL  CULTURES 